Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram

ACS Nano

Volumn 7, Issue 7, 2013, Pages 5858-5869

  Duan, Xiaopin ^a,b   Xiao, Jisheng ^a   Yin, Qi ^a   Zhang, Zhiwen ^a   Yu, Haijun ^a   Mao, Shirui ^b   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

combination therapy; disulfiram; doxorubicin; multidrug resistance; pH sensitive; polymeric micelles; temporal release

Indexed keywords

COMBINATION THERAPY; DISULFIRAM; DOXORUBICIN; MULTIDRUG RESISTANCE; PH SENSITIVE; POLYMERIC MICELLE; TEMPORAL RELEASE;

CELL DEATH; DISEASES; FUNCTIONAL POLYMERS; MICELLES; STYRENE;

LOADING;

ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; DISULFIRAM; MICELLE; NANOCAPSULE; POLYMER;

ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; FEMALE; MATERIALS TESTING; METABOLISM; MICELLE; MOUSE; NUDE MOUSE; PATHOLOGY; PH; TREATMENT OUTCOME; TUMOR CELL LINE; ARTICLE; BREAST TUMOR;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DIFFUSION; DISULFIRAM; FEMALE; HYDROGEN-ION CONCENTRATION; MATERIALS TESTING; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; NANOCAPSULES; POLYMERS; TREATMENT OUTCOME;

EID: 84880814226     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn4010796     Document Type: Article

References (40)

1. Woodcock, J.; Griffin, J. P.; Behrman, R. E. Development of Novel Combination Therapies N. Engl. J. Med. 2011, 364, 985-987
2. Jabr-Milane, L. S.; van Vlerken, L. E.; Yadav, S.; Amiji, M. M. Multi-functional Nanocarriers to Overcome Tumor Drug Resistance Cancer Treat. Rev. 2008, 34, 592-602
3. Hu, C.-M. J.; Aryal, S.; Zhang, L. Nanoparticle-Assisted Combination Therapies for Effective Cancer Treatment Ther. Delivery 2010, 1, 323-334
4. Lehar, J.; Krueger, A. S.; Avery, W.; Heilbut, A. M.; Johansen, L. M.; Price, E. R.; Rickles, R. J.; Short, G. F., III; Staunton, J. E.; Jin, X. et al. Synergistic Drug Combinations Tend to Improve Therapeutically Relevant Selectivity Nat. Biotechnol. 2009, 27, 659-666
5. Hu, C.-M. J.; Zhang, L. Nanoparticle-based Combination Therapy toward Overcoming Drug Resistance in Cancer Biochem. Pharmacol. 2012, 83, 1104-1111
6. Greco, F.; Vicent, M. J. Combination Therapy: Opportunities and Challenges for Polymer-Drug Conjugates as Anticancer Nanomedicines Adv. Drug Delivery Rev. 2009, 61, 1203-1213
7. Kolishetti, N.; Dhar, S.; Valencia, P. M.; Lin, L. Q.; Karnik, R.; Lippard, S. J.; Langer, R.; Farokhzad, O. C. Engineering of Self-assembled Nanoparticle Platform for Precisely Controlled Combination Drug Therapy Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 17939-17944
8. Chen, H.; Pazicni, S.; Krett, N. L.; Ahn, R. W.; Penner-Hahn, J. E.; Rosen, S. T.; O'Halloran, T. V. Coencapsulation of Arsenic- and Platinum-based Drugs for Targeted Cancer Treatment Angew. Chem., Int. Ed. 2009, 48, 9295-9299
9. Duan, X. P.; Li, Y. P. Physicochemical Characteristics of Nanoparticles Affect Circulation, Biodistribution, Cellular Internalization, and Trafficking Small 2013, 9, 1521-1532
10. Kastantin, M.; Missirlis, D.; Black, M.; Ananthanarayanan, B.; Peters, D.; Tirrell, M. Thermodynamic and Kinetic Stability of DSPE-PEG(2000) Micelles in the Presence of Bovine Serum Albumin J. Phys. Chem. B 2010, 114, 12632-12640
11. Dong, H.; Dube, N.; Shu, J. Y.; Seo, J. W.; Mahakian, L. M.; Ferrara, K. W.; Xu, T. Long-Circulating 15 nm Micelles Based on Amphiphilic 3-Helix Peptide-PEG Conjugates ACS Nano 2012, 6, 5320-5329
12. Xiao, K.; Li, Y.; Luo, J.; Lee, J. S.; Xiao, W.; Gonik, A. M.; Agarwal, R. G.; Lam, K. S. The Effect of Surface Charge on in vivo Biodistribution of PEG-Oligocholic Acid Based Micellar Nanoparticles Biomaterials 2011, 32, 3435-3446
13. Loo, T. W.; Bartlett, M. C.; Clarke, D. M. Disulfiram Metabolites Permanently Inactivate the Human Multidrug Resistance P-glycoprotein Mol. Pharmaceutics 2004, 1, 426-433
14. Loo, T. W.; Clarke, D. M. Blockage of Drug Resistance in vitro by Disulfiram, A Drug Used To Treat Alcoholism J. Natl. Cancer Inst. 2000, 92, 898-902
15. Regev, R.; Yeheskely-Hayon, D.; Katzir, H.; Eytan, G. D. Transport of Anthracyclines and Mitoxantrone Across Membranes by A Flip-Flop Mechanism Biochem. Pharmacol. 2005, 70, 161-169
16. Krylova, O. O.; Melik-Nubarov, N. S.; Badun, G. A.; Ksenofontov, A. L.; Menger, F. M.; Yaroslavov, A. A. Pluronic L61 Accelerates Flip-Flop and Transbilayer Doxorubicin Permeation Chem.-Eur. J. 2003, 9, 3930-3936
17. Decorti, G.; Peloso, I.; Favarin, D.; Klugmann, F. B.; Candussio, L.; Crivellato, E.; Mallardi, F.; Baldini, L. Handling of Doxorubicin by the LLC-PK1 Kidney Epithelial Cell Line J. Pharmacol. Exp. Ther. 1998, 286, 525-530
18. Regev, R.; Eytan, G. D. Flip-Flop of Doxorubicin across Erythrocyte and Lipid Membranes Biochem. Pharmacol. 1997, 54, 1151-1158
19. Hillaireau, H.; Couvreur, P. Nanocarriers' Entry into the Cell: Relevance to Drug Delivery Cell. Mol. Life Sci. 2009, 66, 2873-2896
20. Fernando, L. P.; Kandel, P. K.; Yu, J.; McNeill, J.; Ackroyd, P. C.; Christensen, K. A. Mechanism of Cellular Uptake of Highly Fluorescent Conjugated Polymer Nanoparticles Biomacromolecules 2010, 11, 2675-2682
21. Nam, H. Y.; Kwon, S. M.; Chung, H.; Lee, S.-Y.; Kwon, S.-H.; Jeon, H.; Kim, Y.; Park, J. H.; Kim, J.; Her, S. et al. Cellular Uptake Mechanism and Intracellular Fate of Hydrophobically Modified Glycol Chitosan Nanoparticles J. Controlled Release 2009, 135, 259-267
22. Wang, F.; Wang, Y.-C.; Dou, S.; Xiong, M.-H.; Sun, T.-M.; Wang, J. Doxorubicin-Tethered Responsive Gold Nanoparticles Facilitate Intracellular Drug Delivery for Overcoming Multidrug Resistance in Cancer Cells ACS nano 2011, 5, 3679-3692
23. Pentassuglia, L.; Graf, M.; Lane, H.; Kuramochi, Y.; Cote, G.; Timolati, F.; Sawyer, D. B.; Zuppinger, C.; Suter, T. M. Inhibition of ErbB2 by Receptor Tyrosine Kinase Inhibitors Causes Myofibrillar Structural Damage without Cell Death in Adult Rat Cardiomyocytes Exp. Cell Res. 2009, 315, 1302-1312
24. Chen, D.; Cui, Q. C.; Yang, H.; Dou, Q. P. Disulfiram, A Clinically Used Anti-alcoholism Drug and Copper-binding Agent, Induces Apoptotic Cell Death in Breast Cancer Cultures and Xenografts via Inhibition of the Proteasome Activity Cancer Res. 2006, 66, 10425-10433
25. Lövborg, H.; Öberg, F.; Rickardson, L.; Gullbo, J.; Nygren, P.; Larsson, R. Inhibition of Proteasome Activity, Nuclear Factor-κB Translocation and Cell Survival by the Antialcoholism Drug Disulfiram Int. J. Cancer 2006, 118, 1577-1580
26. Yip, N. C.; Fombon, I. S.; Liu, P.; Brown, S.; Kannappan, V.; Armesilla, A. L.; Xu, B.; Cassidy, J.; Darling, J. L.; Wang, W. Disulfiram Modulated ROS-MAPK and NF-κB Pathways and Targeted Breast Cancer Cells with Cancer Stem Cell-like Properties Br. J. Cancer 2011, 104, 1564-1574
27. Morrison, B. W.; Doudican, N. A.; Patel, K. R.; Orlow, S. J. Disulfiram Induces Copper-dependent Stimulation of Reactive Oxygen Species and Activation of the Extrinsic Apoptotic Pathway in Melanoma Melanoma Res. 2010, 20, 11-20
28. Wang, W.; McLeod, H. L.; Cassidy, J. Disulfiram-Mediated Inhibition of NF-κB Activity Enhances Cytotoxicity of 5-Fluorouracil in Human Colorectal Cancer Cell Lines Int. J. Cancer 2003, 104, 504-511
29. Guo, X.; Xu, B.; Pandey, S.; Goessl, E.; Brown, J.; Armesilla, A. L.; Darling, J. L.; Wang, W. Disulfiram/Copper Complex Inhibiting NF-κB Activity and Potentiating Cytotoxic Effect of Gemcitabine on Colon and Breast Cancer Cell Lines Cancer Lett. 2010, 290, 104-113
30. Pozza, E. D.; Donadelli, M.; Costanzo, C.; Zaniboni, T.; Dando, I.; Franchini, M.; Arpicco, S.; Scarpa, A.; Palmieri, M. Gemcitabine Response in Pancreatic Adenocarcinoma Cells Is Synergistically Enhanced by Dithiocarbamate Derivatives Free Radical Biol. Med. 2011, 50, 926-933
31. Xu, B.; Shi, P.; Fombon, I. S.; Zhang, Y.; Huang, F.; Wang, W.; Zhou, S. Disulfiram/Copper Complex Activated JNK/c-jun Pathway and Sensitized Cytotoxicity of Doxorubicin in Doxorubicin Resistant Leukemia HL60 Cells Blood Cells, Mol., Dis. 2011, 47, 264-269
32. Reinhardt, H. C.; Hasskamp, P.; Schmedding, I.; Morandell, S.; van Vugt, M. A. T. M.; Wang, X.; Linding, R.; Ong, S.-E.; Weaver, D.; Carr, S. A. et al. DNA Damage Activates A Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization Mol. Cell 2010, 40, 34-49
33. Huang, S.; Shao, K.; Liu, Y.; Kuang, Y.; Li, J.; An, S.; Guo, Y.; Ma, H.; Chen, J. Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antiangiogenesis and Apoptosis ACS Nano 2013, 7, 2860-2871
34. Li, L.; Guan, Y.; Liu, H.; Hao, N.; Liu, T.; Meng, X.; Fu, C.; Li, Y.; Qu, Q.; Zhang, Y. et al. Silica Nanorattle-Doxorubicin-Anchored Mesenchymal Stem Cells for Tumor-Tropic Therapy ACS Nano 2011, 5, 7462-7470
35. Arrowsmith, J. Trial Watch: Phase II Failures: 2008-2010 Nat. Rev. Drug Discovery 2011, 10, 328-329
36. Arrowsmith, J. Trial Watch: Phase III and Submission Failures: 2007-2010 Nat. Rev. Drug Discovery 2011, 10, 87-87
37. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting Multidrug Resistance in Cancer Nat. Rev. Drug Discovery 2006, 5, 219-234
38. Eckhardt, B. L.; Francis, P. A.; Parker, B. S.; Anderson, R. L. Strategies for the Discovery and Development of Therapies for Metastatic Breast Cancer Nat. Rev. Drug Discovery 2012, 11, 479-497
39. Adiseshaiah, P. P.; Hall, J. B.; McNeil, S. E. Nanomaterial Standards for Efficacy and Toxicity Assessment Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2009, 2, 99-112
40. Duan, X. P.; Xiao, J. S.; Yin, Q.; Zhang, Z. W.; Mao, S. R.; Li, Y. P. Amphiphilic Graft Copolymer Based on Poly(styrene-co-maleic anhydride) with Low Molecular Weight Polyethylenimine for Efficient Gene Delivery Int. J. Nanomed. 2012, 7, 4961-4972